Sanofi India is currently trading at Rs. 4160.00, up by 102.95 points or 2.54% from its previous closing of Rs. 4057.05 on the BSE.
The scrip opened at Rs. 4074.65 and has touched a high and low of Rs. 4160.00 and Rs. 4074.65 respectively. So far 509 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 4930.00 on 29-Mar-2017 and a 52 week low of Rs. 3901.00 on 06-Sep-2017.
Last one week high and low of the scrip stood at Rs. 4160.00 and Rs. 4022.00 respectively. The current market cap of the company is Rs. 9534.68 crore.
The promoters holding in the company stood at 60.40%, while Institutions and Non-Institutions held 27.95% and 11.66% respectively.
Sanofi India has expanded its consumer healthcare portfolio with a new addition in the pain-care segment – Combiflam ICYHOT, a topical analgesic. This over-the-counter (OTC) product is available in two formats — gel and spray, for instant and long-lasting relief to people suffering from muscle pains and sprains. On application of Combiflam ICYHOT, it produces an icy and a hot sensation. The icy action reduces the pain, while the hot action relaxes stiff muscles to give effective pain relief.
Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets and animal health.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: